Candida overgrowth symptoms: what the evidence really says

The symptoms attributed to gut candida overgrowth - bloating, gas, sugar cravings, brain fog, fatigue and loose stools - are real, but they are also completely non-specific, which is exactly why this topic is so muddled. Candida is a normal resident of most people’s intestines, so finding it proves nothing on its own. This guide draws the lines the internet usually blurs: between harmless colonisation, a genuinely contested “overgrowth,” the better-defined entity of small intestinal fungal overgrowth (SIFO), and the serious infections that are a different matter entirely.

The candida spectrum, properly drawn

Almost all confusion here comes from collapsing four very different situations into one word. They are not the same, and they do not carry the same weight.

This matters because the same word is used to sell a stool test, describe a real endoscopic finding, and name a life-threatening ICU infection. When someone says “candida,” the first question is always: which of these?

Symptoms - and their limits

The symptoms commonly attributed to gut candida - bloating, wind, indigestion, nausea, loose stools, intense sugar cravings, fatigue and brain fog - overlap almost entirely with IBS and with SIBO. That overlap is the core difficulty: there is no symptom, or cluster of symptoms, that points specifically to yeast rather than bacteria or simple functional gut disorder. Anyone who tells you a symptom checklist can diagnose candida is overstating what symptoms can do. They can raise the question; they cannot answer it.

SIFO: the part with real evidence

Small intestinal fungal overgrowth is the most defensible version of this idea. When researchers sampled fluid directly from the small intestine in people with unexplained gut symptoms, they found fungal overgrowth - usually Candida - in roughly a quarter of them (about 25-26% across two studies).² The same work flagged two predisposing factors that should sound familiar from the SIBO story: impaired small-bowel motility and proton pump inhibitor use.

Two honest caveats come with this. The studies are small and single-centre, and - crucially - it is still not proven that eradicating the fungi reliably resolves symptoms. SIFO is a real finding in search of firmer treatment evidence, not a settled disease with a settled cure.

What drives overgrowth

Where overgrowth does occur, the usual contributors are the things that disturb the balance keeping Candida in check: broad-spectrum antibiotics (which clear the competing bacteria), acid suppression, impaired motility, a very high-sugar diet, and immune compromise or corticosteroid use. In healthy, immune-competent people, the gut’s own ecology is remarkably good at containing yeast - which is why “overgrowth” as a chronic illness in otherwise well people remains contested.

The NHS gap

The NHS recognises and treats candida that it can define: oral, oesophageal and vaginal thrush, and serious invasive candidiasis.³ What it generally does not do is test for or treat a functional “gut candida overgrowth” in otherwise healthy people - and there is a sound reason. NHS laboratory guidance is explicit that a positive Candida culture from an asymptomatic person “reflects colonisation which does not require treatment.”³ Because the yeast is a normal resident, finding it is expected, not diagnostic.

The result is a familiar gap: people with genuine symptoms, a normal NHS work-up, and no framework offered for what to investigate next. That gap is real - but it is better filled with SIFO-aware assessment and the SIBO differential than with unvalidated candida testing.

Testing: what’s reliable and what isn’t

This is where money is most often wasted.

Organic acids test (OAT) / urinary D-arabinitol. Marketed as a candida marker, but its validation is mostly in invasive candidiasis in immunocompromised patients, with low and variable sensitivity.⁵ As a way to diagnose “gut candida” in a generally well person, the evidence is weak.⁶

Stool culture or PCR. Detects Candida readily - but cannot tell normal colonisation from disease. A positive result in someone without clear clinical signs reflects the 50-70% who simply carry it.³

Small-bowel (duodenal) aspirate. The closest thing to a gold standard, because it samples the small intestine directly - but it requires an endoscopy, so it is reserved for selected cases.²

Treatment options

Where antifungal treatment is genuinely warranted - confirmed SIFO, or candida overgrowth in a susceptible person under clinical guidance - the main choices differ sharply in how they behave in the body.

Nystatin is a polyene antifungal that is barely absorbed from the gut, so it acts locally in the gut lumen with very little systemic effect, and almost no drug interactions.⁷ That makes it the natural first thought for a problem confined to the bowel. Its uses, UK dosing and limits have a dedicated guide: nystatin for gut candida.

Fluconazole is the opposite: a systemic azole that is well absorbed and distributes throughout the body, which makes it powerful but also means real drug interactions (it inhibits liver enzymes that handle many other medicines) and a need for caution in liver disease.⁸ It is the right tool for systemic or oesophageal disease, not necessarily for a purely luminal problem.

Herbal antifungals - caprylic acid, undecylenic acid, oregano oil, berberine - are popular, but here the honesty matters most: the evidence is overwhelmingly laboratory-based.¹³ They show activity against Candida in a dish; robust human gut trials do not exist. They are plausible adjuncts, not proven treatments.

Biofilms - and the OligoG question

Part of why fungal overgrowth can be stubborn is the biofilm: a protective matrix Candida builds around itself that can make it dramatically less susceptible to antifungals than free-floating yeast.¹⁰ This is the rationale behind interest in “biofilm disruptors” - including OligoG, an alginate compound that, in a 2023 laboratory study, made nystatin more potent against Candida.⁹

“Die-off” versus a reaction that means stop

Starting an antifungal sometimes brings a short-lived flare of malaise - the so-called “die-off” or Herxheimer-like reaction, attributed to dying organisms releasing inflammatory products. It is worth being clear-eyed: the concept is well established for certain bacterial infections, but the evidence for a true yeast “die-off” is very thin, resting on little more than isolated case reports.¹¹¹²

Whatever you call it, the safety logic is simple and important: transient, mild symptoms that settle are one thing; an allergic or serious adverse reaction is another, and it overrides any “push through it” advice.

This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.